Marcus R. Breese
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marcus R. Breese has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- E. Alejandro Sweet-Cordero
University of California San Francisco 8 Division of Pediatric Oncology, Department of Pediatrics San Francisco, CA
64 shared publications - Stanley G. Leung
Division of Radiation Oncology, UCSF, San Francisco, United States of America
47 shared publications - Alex G. Lee
University of California, San Francisco 2 San Francisco, CA
46 shared publications - Leanne C. Sayles
Division of Pediatric Oncology, UCSF, San Francisco, United States of America
46 shared publications - Maria V. Pons Ventura
Division of Pediatric Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, California
45 shared publications - Andrew S. Clugston
Division of Pediatric Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, California
40 shared publications
Latest Publications
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S3. TFs per subtype related to Figure 2.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S3. TFs per subtype related to Figure 2.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S7. Information about the patients related to Figure 5B and Supplementary Figure S5C.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S7. Information about the patients related to Figure 5B and Supplementary Figure S5C.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S4. SEs per PDX-cell line related to Figure 3.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S4. SEs per PDX-cell line related to Figure 3.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S11. Drug screen tested in the PDX-cell lines panel related to Supplementary Figure S8A.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S11. Drug screen tested in the PDX-cell lines panel related to Supplementary Figure S8A.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S8. IHC TMA quantification related to Figure 5E-5F.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S8. IHC TMA quantification related to Figure 5E-5F.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Figure S3 shows the superenhancer signatures and pathway analysis, related to Figure 3.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Figure S3 shows the superenhancer signatures and pathway analysis, related to Figure 3.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S1. Summary of the samples used in this study related to Figure 1.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S1. Summary of the samples used in this study related to Figure 1.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Figure S2 shows the characterization of the enriched TF set per subtype, related to Figure 2.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Figure S2 shows the characterization of the enriched TF set per subtype, related to Figure 2.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S9. Detailed peak and gene information from PDX- single cell multiome experiment related to Figure 6.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S9. Detailed peak and gene information from PDX- single cell multiome experiment related to Figure 6.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S3. TFs per subtype related to Figure 2.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S3. TFs per subtype related to Figure 2.